Mywell Denosumab Biosimilar Gains Two Additional Cancer-Related Indications in China
Mywell Bio’s denosumab biosimilar has received approval in China for two additional indications, including bone metastases from solid tumors. The biosimilar demonstrated equivalence to the reference drug in a phase 3 trial and has signed supply agreements with 33 countries, inclu
2026-05-21


